메뉴 건너뛰기




Volumn 22, Issue 3, 2007, Pages 319-323

Antipsychotic use in older adults with Parkinson's disease

Author keywords

Antipsychotics; Parkinson's disease; Psychosis

Indexed keywords

BROMOCRIPTINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; OLANZAPINE; PERGOLIDE; PRAMIPEXOLE; QUETIAPINE; RISPERIDONE; ROPINIROLE; SELEGILINE;

EID: 34147166076     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.21192     Document Type: Article
Times cited : (27)

References (12)
  • 1
    • 0036244907 scopus 로고    scopus 로고
    • Antipsychotics and Parkinson's disease: Association with disease and drug choice during the first 5 years of antiparkinsonian drug treatment
    • van de Vijver DA, Roos RA, Jansen PA, Porsius AJ, de Boer A. Antipsychotics and Parkinson's disease: association with disease and drug choice during the first 5 years of antiparkinsonian drug treatment. Eur J Clin Pharmacol 2002;58:157-161.
    • (2002) Eur J Clin Pharmacol , vol.58 , pp. 157-161
    • van de Vijver, D.A.1    Roos, R.A.2    Jansen, P.A.3    Porsius, A.J.4    de Boer, A.5
  • 2
    • 0031865551 scopus 로고    scopus 로고
    • Managing the neuropsychiatric symptoms of Parkinson's disease
    • Lieberman A. Managing the neuropsychiatric symptoms of Parkinson's disease. Neurology 1998;50:S33-S38.
    • (1998) Neurology , vol.50
    • Lieberman, A.1
  • 3
    • 0034973443 scopus 로고    scopus 로고
    • An algorithm (decision tree) for the management of Parkinson's disease: Treatment guidelines
    • Olanow CW, Watts RL, Roller WC. An algorithm (decision tree) for the management of Parkinson's disease: treatment guidelines. Neurology 2001;56:S1-S37.
    • (2001) Neurology , vol.56
    • Olanow, C.W.1    Watts, R.L.2    Roller, W.C.3
  • 4
    • 33646107153 scopus 로고    scopus 로고
    • Practice parameter: Evaluation and treatment of depression, psychosis and dementia in Parkinson's disease (an evidence-based review)
    • Miyasaki JM, Shannon K, Voon V, et al. Practice parameter: evaluation and treatment of depression, psychosis and dementia in Parkinson's disease (an evidence-based review). Neurology 2006; 66:996-1002.
    • (2006) Neurology , vol.66 , pp. 996-1002
    • Miyasaki, J.M.1    Shannon, K.2    Voon, V.3
  • 5
    • 0032916601 scopus 로고    scopus 로고
    • Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: A community-based study
    • Aarsland D, Larsen JP, Cummins JL, Laake K. Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study. Arch Neurol 1999;56:595-601.
    • (1999) Arch Neurol , vol.56 , pp. 595-601
    • Aarsland, D.1    Larsen, J.P.2    Cummins, J.L.3    Laake, K.4
  • 6
    • 33644875033 scopus 로고    scopus 로고
    • Mental health-related drug utilization among the older adult population: Prevalence, trends and costs
    • Mamdani M, Rapoport M, Shulman KI, Herrmann N, Rochon PA. Mental health-related drug utilization among the older adult population: prevalence, trends and costs. Am J Geriatr Psychiatry 2005;13:892-900.
    • (2005) Am J Geriatr Psychiatry , vol.13 , pp. 892-900
    • Mamdani, M.1    Rapoport, M.2    Shulman, K.I.3    Herrmann, N.4    Rochon, P.A.5
  • 7
    • 0032726757 scopus 로고    scopus 로고
    • Prevalence, clinical characteristics, and pharmacologic treatment of Parkinson's disease in residents in long-term care facilities: SAGE study group
    • Lapane KL, Fernandez HH, Friedman JH. Prevalence, clinical characteristics, and pharmacologic treatment of Parkinson's disease in residents in long-term care facilities: SAGE study group. Pharmacotherapy 1999;19:1321-1327.
    • (1999) Pharmacotherapy , vol.19 , pp. 1321-1327
    • Lapane, K.L.1    Fernandez, H.H.2    Friedman, J.H.3
  • 8
    • 25144465916 scopus 로고    scopus 로고
    • Atypical antipsychotics and parkinsonism
    • Rochon PA, Stukel TA, Sykora K, et al. Atypical antipsychotics and parkinsonism. Arch Intern Med 2005;165:1882-1888.
    • (2005) Arch Intern Med , vol.165 , pp. 1882-1888
    • Rochon, P.A.1    Stukel, T.A.2    Sykora, K.3
  • 9
    • 0038780020 scopus 로고    scopus 로고
    • Treatment of psychosis in Parkinson's disease: Safety considerations
    • Fernandez HH, Trieschmann ME, Friedman JH. Treatment of psychosis in Parkinson's disease: safety considerations. Drug Safety 2003;26:643-659.
    • (2003) Drug Safety , vol.26 , pp. 643-659
    • Fernandez, H.H.1    Trieschmann, M.E.2    Friedman, J.H.3
  • 10
    • 19544378167 scopus 로고    scopus 로고
    • Neuroleptic sensitivity in Parkinson's disease and parkinsonian dementias
    • Aarsland D, Perry R, Larsen JP, et al. Neuroleptic sensitivity in Parkinson's disease and parkinsonian dementias. J Clin Psychiatry 2005;66:633-637.
    • (2005) J Clin Psychiatry , vol.66 , pp. 633-637
    • Aarsland, D.1    Perry, R.2    Larsen, J.P.3
  • 11
    • 0036221550 scopus 로고    scopus 로고
    • Atypical antipsychotics: Mechanism of action
    • Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry 2002;47:27-38.
    • (2002) Can J Psychiatry , vol.47 , pp. 27-38
    • Seeman, P.1
  • 12
    • 0024854809 scopus 로고
    • The ratio of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs
    • Meltzer HY, Matrusbata S, Lee J-C. The ratio of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull 1989;25:390-392.
    • (1989) Psychopharmacol Bull , vol.25 , pp. 390-392
    • Meltzer, H.Y.1    Matrusbata, S.2    Lee, J.-C.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.